Conclusions and Future Prospects
Anti-B-cell therapy, in particular treatment with rituximab, is a promising approach for immunotherapy of neurological diseases, and it has the potential to produce long-lasting benefits. The reported excellent tolerance of rituximab administered in combination with other immunosuppressants is an important advantage, but close monitoring will be required to promptly identify any long-term sequelae or unforeseen adverse effects. Newer monoclonal antibodies designed to target B-cell survival factors might prove to be even more effective than rituximab, because they can also affect the production of immunoglobulin and antibodies by plasma cells. The B cell is an attractive target for immunotherapeutic interventions, and controlled trials with rituximab and other new agents that work through similar mechanisms are warranted for the treatment of neurological disorders.
CLICK HERE for subscription information about this journal.
The author thanks Dr R Raju for performing the B-cell counts in his patients treated with rituximab.Reprint Address
Marinos C Dalakas, Director of Neuromuscular Division, Thomas Jefferson University, 900 Walnut Street, Suite 200, Philadelphia, PA 19107, USA; E-mail: email@example.com
Neuroinflammation and Neuromuscular Diseases Section, Imperial College London, Burlington Danes Building, Office E412, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK; E-mail: firstname.lastname@example.org
Nat Clin Pract Neurol. 2008;4(10):557-567. © 2008 Nature Publishing Group
Cite this: B Cells As Therapeutic Targets In Autoimmune Neurological Disorders - Medscape - Oct 01, 2008.